Short Interest in PDS Biotechnology Co. (NASDAQ:PDSB) Grows By 20.7%

PDS Biotechnology Co. (NASDAQ:PDSB) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 4,670,000 shares, a growth of 20.7% from the February 13th total of 3,870,000 shares. Approximately 13.8% of the company’s stock are short sold. Based on an average daily volume of 630,100 shares, the days-to-cover ratio is currently 7.4 days.

Hedge Funds Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of PDSB. Raymond James Financial Inc. bought a new stake in shares of PDS Biotechnology during the 4th quarter valued at $26,000. Jane Street Group LLC bought a new position in shares of PDS Biotechnology in the fourth quarter worth about $58,000. Marshall Wace LLP raised its position in shares of PDS Biotechnology by 38.4% during the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after buying an additional 10,837 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of PDS Biotechnology in the fourth quarter worth $89,000. Finally, Two Sigma Investments LP lifted its holdings in shares of PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after buying an additional 48,132 shares in the last quarter. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on PDSB shares. B. Riley decreased their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of PDS Biotechnology in a report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, PDS Biotechnology has an average rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Stock Performance

PDS Biotechnology stock traded up $0.05 during midday trading on Tuesday, reaching $1.39. 387,683 shares of the company traded hands, compared to its average volume of 568,546. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. PDS Biotechnology has a 12 month low of $1.13 and a 12 month high of $5.00. The firm has a market capitalization of $53.09 million, a price-to-earnings ratio of -1.20 and a beta of 1.68. The business has a 50 day moving average of $1.43 and a two-hundred day moving average of $2.24.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.